Lara Meisner - Nov 15, 2022 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role: General Counsel and Secretary
Signature: /s/ Kristian Humer, Attorney-in-Fact for Lara Meisner
Stock symbol: VRDN
Transactions as of: Nov 15, 2022
Transactions value $: -$65,406
Form type: 4
Date filed: 11/16/2022, 05:45 PM
Previous filing: Feb 3, 2022
Next filing: Dec 14, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VRDN	Common Stock	Options Exercise	$114K	+8.13K		$14.00	8.13K	Nov 15, 2022	Direct
transaction	VRDN	Common Stock	Sale	-$179K	-8.13K	-100%	$22.05	0	Nov 15, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VRDN	Stock Option (Right to Buy)	Options Exercise	$0	-8.13K	-27.08%	$0.00	21.9K	Nov 15, 2022	Common Stock	8.13K	$14.00	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $21.04 to $22.845. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2	The option vested 25% on September 22, 2022 and the remainder vests in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.

Content

This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $21.04 to $22.845. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

The option vested 25% on September 22, 2022 and the remainder vests in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.